| __timestamp | Amgen Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 612613000000 |
| Thursday, January 1, 2015 | 4846000000 | 650773000000 |
| Friday, January 1, 2016 | 5062000000 | 619061000000 |
| Sunday, January 1, 2017 | 4870000000 | 628106000000 |
| Monday, January 1, 2018 | 5332000000 | 717599000000 |
| Tuesday, January 1, 2019 | 5150000000 | 964737000000 |
| Wednesday, January 1, 2020 | 5730000000 | 875663000000 |
| Friday, January 1, 2021 | 5368000000 | 886361000000 |
| Saturday, January 1, 2022 | 5414000000 | 997309000000 |
| Sunday, January 1, 2023 | 6179000000 | 1053819000000 |
| Monday, January 1, 2024 | 7096000000 | 1053819000000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Amgen Inc. and Takeda Pharmaceutical Company Limited have showcased contrasting strategies. From 2014 to 2023, Amgen's SG&A expenses grew modestly by approximately 31%, reflecting a steady approach to cost management. In contrast, Takeda's expenses surged by around 72%, indicating aggressive expansion and investment strategies.
Amgen's expenses peaked in 2023, while Takeda consistently increased its spending, reaching a significant milestone in the same year. This divergence highlights Amgen's focus on efficiency, whereas Takeda's strategy leans towards growth and market penetration. The data for 2024 is incomplete, leaving room for speculation on future trends. As these giants continue to evolve, their SG&A management will remain a key indicator of their strategic priorities.
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Amgen Inc. or Galapagos NV
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Catalent, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Takeda Pharmaceutical Company Limited and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights